Celgene drug fails to extend survival in lymphoma study

(Reuters) - Celgene Corp said on Monday that its flagship drug Revlimid failed to extend survival as a maintenance therapy for a type of blood cancer after patients had responded to prior treatment. < div class="feedflare" > < a href="http://feeds.feedburner.com/~ff/reuters/healthNews?a=6gJL44kO8vw:9Zma1I7-XPQ:yIl2AUoC8zA" > < img src="http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA" border="0" > < /img > < /a > < a href="http://feeds.feedburner.com/~ff/reuters/healthNews?a=6gJL44kO8vw:9Zma1I7-XPQ:F7zBnMyn0Lo" > < img src="http://feeds.feedburner.com/~ff/reuters/healthNews?i=6gJL44kO8vw:9Zma1I7-XPQ:F7zBnMyn0Lo" border="0" > < /img > < /a > < a href="http://feeds.feedburner.com/~ff/reuters/healthNews?a=6gJL44kO8vw:9Zma1I7-XPQ:V_sGLiPBpWU" > < img src="http://feeds.feedburner.com/~ff/reuters/healthNews?i=6gJL44kO8vw:9Zma1I7-XPQ:V_sGLiPBpWU" border="0" > < /img > < /a > < /div > < img src="http://feeds.feedburner.com/~r/reuters/healthNews/~4/6gJL44kO8vw" height="1" width="1" alt=""/ >

Source: Reuters: Health - July 25, 2016 Category: Consumer Health News Tags: healthNews Source Type: news